We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+0.65%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$73.9B
AUM Growth
-$2.32B
(-3%)
Cap. Flow
-$2.03B
Cap. Flow
% of AUM
-2.75%
Top 10 Holdings %
Top 10 Hldgs %
22.54%
Holding
3,088
New
92
Increased
1,359
Reduced
1,564
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$60.7M |
| 2 |
Analog Devices
ADI
|
+$46.1M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$37.3M |
| 4 |
Match Group
MTCH
|
+$28.2M |
| 5 |
GXO Logistics
GXO
|
+$19.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$89.3M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$78.9M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$77.4M |
| 4 |
Apple
AAPL
|
+$77M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$70.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.91% |
| 2 | Financials | 14.2% |
| 3 | Healthcare | 13.07% |
| 4 | Consumer Discretionary | 12.09% |
| 5 | Communication Services | 9.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2626
KRONOS Worldwide
KRO
$989M
| $418K | ﹤0.01% |
33,722
+299
| +0.9% | +$3.96K |
|
|
STXB
2627
DELISTED
Spirit of Texas Bancshares, Inc. Common Stock
STXB
| $418K | ﹤0.01% |
17,258
+370
| +2% | +$8.51K |
|
|
DSKE
2628
DELISTED
Daseke, Inc. Common Stock
DSKE
| $417K | ﹤0.01% |
45,320
+1,205
| +3% | +$10K |
|
2629
Atomera
ATOM
$214M
| $416K | ﹤0.01% |
18,030
+898
| +5% | +$19.5K |
|
2630
Relmada Therapeutics
RLMD
$527M
| $415K | ﹤0.01% |
15,826
+673
| +4% | +$18K |
|
2631
UroGen Pharma
URGN
$2.29B
| $411K | ﹤0.01% |
24,408
+505
| +2% | +$8.01K |
|
2632
Alaunos Therapeutics
TCRT
$4.86M
| $409K | ﹤0.01% |
1,499
+42
| +3% | +$12.8K |
|
2633
Caesarstone
CSTE
$79.5M
| $408K | ﹤0.01% |
32,838
-136
| -0.4% | -$1.82K |
|
2634
FS Bancorp
FSBW
$320M
| $405K | ﹤0.01% |
11,694
+1,102
| +10% | +$37.8K |
|
2635
Noodles & Co
NDLS
$107M
| $405K | ﹤0.01% |
4,294
+237
| +6% | +$23.2K |
|
2636
Custom Truck One Source
CTOS
$2.37B
| $404K | ﹤0.01% |
43,310
+31,165
| +257% | +$262K |
|
2637
Kiniksa Pharmaceuticals
KNSA
$5.93B
| $404K | ﹤0.01% |
35,469
-968
| -3% | -$12.6K |
|
2638
Lexicon Pharmaceuticals
LXRX
$1.1B
| $404K | ﹤0.01% |
83,991
+2,199
| +3% | +$9.03K |
|
2639
Privia Health
PRVA
$2.87B
| $404K | ﹤0.01% |
17,133
+940
| +6% | +$32.8K |
|
2640
Xometry
XMTR
$5.34B
| $404K | ﹤0.01% |
+7,003
| New | +$485K |
|
2641
Teekay Tankers
TNK
$2.68B
| $403K | ﹤0.01% |
27,758
+581
| +2% | +$7.12K |
|
|
PCSB
2642
DELISTED
PCSB Financial Corporation
PCSB
| $403K | ﹤0.01% |
21,851
+460
| +2% | +$8.39K |
|
2643
Immunovant
IMVT
$8.25B
| $401K | ﹤0.01% |
46,090
+1,880
| +4% | +$17K |
|
2644
Lindblad Expeditions
LIND
$2.22B
| $400K | ﹤0.01% |
27,432
+1,425
| +5% | +$20K |
|
|
NAPA
2645
DELISTED
The Duckhorn Portfolio, Inc.
NAPA
| $399K | ﹤0.01% |
17,434
+1,331
| +8% | +$29K |
|
2646
ASML
ASML
$669B
| $398K | ﹤0.01% |
+534
| New | +$420K |
|
2647
National CineMedia
NCMI
$378M
| $398K | ﹤0.01% |
11,193
-780
| -7% | -$25.3K |
|
2648
Playboy Inc
PLBY
$141M
| $397K | ﹤0.01% |
16,846
+8,869
| +111% | +$238K |
|
2649
Accuray
ARAY
$34M
| $395K | ﹤0.01% |
99,994
+1,522
| +2% | +$6.04K |
|
2650
Outdoor Holding Co
POWW
$247M
| $395K | ﹤0.01% |
64,216
+7,047
| +12% | +$50.8K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2021 Portfolio in Review
As of Q3 2021, RhumbLine Advisers held 3,088 positions worth $73.9B, down 3% from $76.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Trading was light in Q3 2021: portfolio turnover was 4.5%. RhumbLine Advisers opened 92 new positions and exited 46, leaving the 3,088-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q3 2021 buy was GXO Logistics: 250,722 shares worth $19.7M.
- RhumbLine Advisers added most to Moderna in Q3 2021, an estimated $60.7M increase.
- RhumbLine Advisers's biggest Q3 2021 reduction was Microsoft, cutting an estimated $89.3M.
- RhumbLine Advisers fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $77.4M.
- RhumbLine Advisers's ten largest holdings make up 23% of its $73.9B portfolio in Q3 2021.
- RhumbLine Advisers opened 92 new positions and closed 46 in Q3 2021.
- RhumbLine Advisers's portfolio value fell 3% quarter-over-quarter to $73.9B.
Based on RhumbLine Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.